To evaluate RXR-PPARγ ligand therapy for synergism in cutaneous T-celllymphoma, a small uncontrolled study evaluated the addition of rosiglitazone tobexarotene monotherapy in four patients with stable or progressive cutaneous T-celllymphoma, showing improvement in skin score (50%) and pruritus (75%) [114]. Here, PPARG is linked to T-cell non-Hodgkin lymphoma.